The phase 3 ASCEMBL trial (NCT03106779) assessed asciminib (Scemblix) at 40 mg twice daily vs bosutinib (Bosulif) at 500 mg once daily in patients with CP-CML who had been treated with 2 or more TKIs.3 A total of 223 patients were randomized 2:1 to active or control therapy with a median follow-up of 14.9 months. At baseline, MCyR was observed in 29.3 of patients in the asciminib arm vs 28.9 in the bosutinib arm. After the data analysis cutoff date, treatment was ongoing in 61.8 vs 28.9 of patients, respectively, with 37.6 and 71.1 discontinuing therapy.
展开▼
